… In this respect, cancer cells may escape from growth inhibition by using alternative growth
… , research-oriented clinical trials with EGFR inhibitors in NSCLC is needed to establish fully …

… these issues for EGFR inhibitors and other … EGFR inhibitors to the EGFR ATP binding
pocket [38,39]. Other known biological resistance mechanisms include MET amplification, EGFR …

… inhibitors of the epidermal growth factor receptor (EGFR), has recently provided new therapeutic
options for the most common lung tumor histology, non-small-cell lung cancer (… in EGFR …

… with EGFR inhibitors. Recently, studies have identified gene mutations targeting the kinase
domain of the EGFR that are related to the response to inhibitors. Most EGFR mutations …

… (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation
(EGFR-mutated lung cancer)… In preclinical models, the EGFR inhibitor AZD9291 has been …

… EGFR inhibitor therapy. Median life expectancy for patients with advanced NSCLC harbouring
an activating EGFR … evolution of lung cancers acquiring resistance to EGFR inhibitors. …

… T790M that is 30–100 fold more potent against EGFR T790M, … EGFR than quinazoline
based EGFR inhibitors in vitro and is effective in murine models of lung cancer driven by EGFR …

… of cells remains viable after EGFR inhibition, despite cell death in the vast majority [96–98,
106, 107]. Our study demonstrated that EGFR inhibition in lung cancer cells generates a drug-…

… EGFR inhibitors were originally investigated as therapeutic agents that might be useful for
all … reviews the still unfolding story of EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. …

… with EGFR inhibitors. Collectively, these results deepen our understanding of resistance to
EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout …